NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Free Report) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 38,236 shares, a drop of 91.8% from the August 31st total of 469,120 shares. Currently, 2.8% of the company’s shares are sold short. Based on an average daily trading volume, of 40,192 shares, the short-interest ratio is presently 1.0 days.
Institutional Trading of NeuroSense Therapeutics
An institutional investor recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP bought a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 100,000 shares of the company’s stock, valued at approximately $77,000. NeuroSense Therapeutics comprises approximately 0.0% of Yorkville Advisors Global LP’s portfolio, making the stock its 24th largest holding. Yorkville Advisors Global LP owned approximately 0.73% of NeuroSense Therapeutics at the end of the most recent reporting period. 1.04% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
NRSN has been the subject of several research reports. HC Wainwright assumed coverage on NeuroSense Therapeutics in a research note on Thursday, September 3rd. They issued a “buy” rating for the company. Weiss Ratings lowered NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $170.00.
NeuroSense Therapeutics Trading Down 6.1%
Shares of NASDAQ:NRSN traded down $0.45 during trading on Friday, hitting $6.95. 8,623 shares of the company’s stock were exchanged, compared to its average volume of 25,064. NeuroSense Therapeutics has a 1-year low of $5.00 and a 1-year high of $26.64. The firm has a 50-day moving average price of $8.93 and a two-hundred day moving average price of $13.15. The firm has a market cap of $13.21 million, a P/E ratio of -0.64 and a beta of 1.60.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.
NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.
See Also
- Five stocks we like better than NeuroSense Therapeutics
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
